This session will focus on the yet unresolved questions in the treatment of acute myeloid leukemia (AML). The focus will be on delineating the genetic of subtypes of AML and how that information can be exploited to improve therapeutic approaches. While substantial progress has been made in understanding the genetics of AML, there are still distinct areas that require major advances. Acute promyelocytic leukemia (APL) is a highly curable form of AML with a distinct genetic alteration, however, the same cannot be said about Blastic Plasmacytoid Dendritic Cell Neoplasm (BPCDN) and therapy-related myeloid neoplasms. This session will focus on the genetic underpinnings of these disorders with the intent to improve outcomes for our patients.
Dr. Jessica Altman will provide a brief overview of the historical treatment of APL and focus on the current state of therapy and remaining issues in this disease: minimizing toxicities (including early death and late complications) and decreasing the burden of treatment.
Dr. David Rizzieri will discuss the biology of Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN) and the approach to treatment of BPCDN. He will also focus on clinical trials in this rare disorder.
Dr. Michael Heuser will review the mutational profiles of therapy-related myeloid neoplasms and provide insight as to how the genetic and clinical background may affect therapeutic approaches.